Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by bringon10baggeron Feb 13, 2021 4:00pm
215 Views
Post# 32562661

RE:RE:RE:RE:RE:RE:Nasdaq

RE:RE:RE:RE:RE:RE:NasdaqCome out to play big pharm's......bring your pots of CASH...cash on hand end of 2020......with these cash positions ....highest bidder wins!

BMSquib 21B
J&J 17B
Roche 12B
Novartis 11B
Sanofi 10B
Amgen 10B
Pfizer 10B
GSK 7B
Merck 7B
Bayer 4B
Lilly 3.5B


crow27 wrote: So True 3burtc, one almosts forgets the other products that ATE has. This Nuance deal was only for otenaproxesu and that was only aprox 10% of the worldwide pharma market.
100 million PLUS royalties for 10% ..................... sweet!! 
ATB could blow this bio market wide open with just otenaproxesu never mind their other products. 
This deal will and has got the attention of all pharma companies and if they have a brain in their head they will also make some sort of deal with ATE.
I would not want to be the guy that works for big pharma and does not bring this to their attention.
In very short order you will be handed your a ss as they walk you out the door.
Next week should be a blast!!


<< Previous
Bullboard Posts
Next >>